ClinicalTrials.gg
CompletedNCT05632393Updated May 12, 2023

A Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women

A Phase 1 interventional study of Daridorexant in Healthy, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-12.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Apr 2023, 3 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

A study to measure daridorexant in breast milk of healthy lactating women

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed in a language understandable to the subject prior to any study-mandated procedure.
  • Healthy lactating female subject aged at least 18 years at Screening.
  • Female subject who has delivered a term infant (≥ 37 weeks' gestation) and who is breastfeeding her infant (and/or pumping) for at least 2 weeks postpartum at Screening; lactation must be well-established to maintain an adequate milk supply with regular breastfeeding (and/or pumping, e.g., 3 to 4 times per day and not providing more than 1 supplemental bottle of formula per day and the infant has not started eating solids). Subjects planning on weaning their infants after enrollment who meet the afore mentioned requirements will be considered for enrollment in the study.
  • Agreement to refrain from breastfeeding any infant with her own milk from Day -1 up to 72 h after study treatment administration.
  • Ability of subject's infant to feed from a bottle or no anticipated compromise of subject's infant's nutrition with time period of refraining from breastfeeding planned during the study.
  • Agreement to collect breast milk from pre-dose (directly prior to study treatment administration) to Day 4 (72 h after study treatment administration) using an electric pump provided by the study site.
  • Must agree to use an acceptable effective method of consistently and correctly (e.g., oral progestin-only contraceptive; implants; intra uterine devices; male or female condom with or without spermicide; cap, diaphragm or sponge with spermicide) from Screening up to at least 72 h after study treatment administration, be sexually inactive, or be in same-sex relationship.

Exclusion criteria

Exclusion Criteria:

  • Known to daridorexant or treatments of the same class, or any of its .
  • History of narcolepsy.
  • Mastitis or other condition that prevents the collection of breast milk from one or both breasts at Screening or on Day -1.
  • History of breast implants, breast augmentation, or breast reduction surgery which prevents the collection of breast milk.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Daridorexant 50 mg

    Daridorexant 50 mg will be administered once in the morning of Day 1.

    Drug: Daridorexant

Interventions

  • Daridorexant will be available as film-coated tablets for oral administration formulated at a strength of 50 mg.

06

What researchers measure

Primary outcomes

  1. Milk pharmacokinetic endpoints: Amount of daridorexant excreted (mg)

    Cumulative amount excreted in breast milk over the collection time

    Time frame: 0 to 72 hours after study treatment administration (Total duration: up to 4 days)

Other outcomes

  1. Milk pharmacokinetic endpoints: Fraction (percentage) of dose excreted in breast milk

    Time frame: 0 to 72 hours after study treatment administration (Total duration: up to 4 days)

  2. Milk pharmacokinetic endpoints: Relative infant daridorexant dose (percentage)

    Percentage of dose that would be consumed by the infant, adjusted to maternal weight and infant weight on Day -1

    Time frame: 0 to 72 hours after study treatment administration (Total duration: up to 4 days)

  3. Plasma pharmacokinetic endpoints: Cmax

    Time frame: 0 to 72 hours after study treatment administration (Total duration: up to 4 days)

  4. Plasma pharmacokinetic endpoints: Tmax

    Time frame: 0 to 72 hours after study treatment administration (Total duration: up to 4 days)

  5. Plasma pharmacokinetic endpoints: AUC0-inf

    Time frame: 0 to 72 hours after study treatment administration (Total duration: up to 4 days)

  6. Plasma pharmacokinetic endpoints: T1/2

    Time frame: 0 to 72 hours after study treatment administration (Total duration: up to 4 days)

  7. Treatment-emergent (S)AEs

    Time frame: Up to end of study (EOS; total duration: up to 46 days)

07

Study locations

1 site
  • Labcorp Clinical Research Unit Inc.
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Apr 2023, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2022
First posted
Nov 30, 2022
StartActual
Jan 16, 2023
Primary completionActual
Apr 30, 2023
CompletionActual
Apr 30, 2023
Last update
May 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05632393
Responsible party
Sponsor
First posted
Nov 30, 2022
Start date
Jan 16, 2023
Primary completion
Apr 30, 2023
Completion
Apr 30, 2023
Last update
May 12, 2023

Study contacts

Clinical Trials
study director · Idosia Pharmaceuticals Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daridorexant

Start the discussion